Reinforcing Treatment May Overcome Breast Cancer Drug Resistance, New Research Suggests
Table of Contents
A novel strategy of continuing—and combining—existing cancer therapies, rather than discontinuing them upon resistance, could offer a significant advantage in slowing tumor growth, according to groundbreaking research published in eLife. The findings challenge conventional wisdom and open new avenues for personalized breast cancer treatment.
Metastatic breast cancer remains a leading cause of cancer-related deaths in women, and a frustrating reality for many patients is the development of resistance to initial treatments. Approximately 30% of patients experience this resistance within two years of starting therapy, highlighting a critical need for innovative approaches (O’Leary et al., 2018; Goel et al., 2018).
The Cell Cycle and the Rise of Resistance
At the heart of many cancers, including breast cancer, lies a dysregulation of cell proliferation. Healthy cell division is a tightly controlled process, with checkpoints ensuring accurate DNA replication. The G1 phase serves as a crucial gatekeeper before replication begins, governed by enzymes called CDK4 and CDK6. These enzymes regulate the activity of the retinoblastoma protein (Rb), a tumor suppressor that normally halts cell cycle progression. When CDK4 and CDK6 inactivate Rb, it releases E2Fs, transcription factors that initiate DNA replication and propel cells into the S phase. Subsequently, CDK2 activity becomes dominant, ensuring the completion of DNA replication.
In hormone-driven breast cancers, CDK4 and CDK6 are often overactive. While drugs targeting these enzymes have shown promise (Johnston et al., 2020), tumors frequently develop resistance. Researchers now believe this resistance often stems from the activation of CDK2, suggesting a need to target multiple points in the cell cycle.
Columbia and Emory Researchers Uncover Key Insights
A team led by Hee Won Yang and colleagues, including first author Jessica Armand, at Columbia University and Emory University, investigated the mechanisms behind this resistance. Their work, published in eLife, focused on both hormone-driven and triple-negative breast cancer cell lines. The researchers subjected cells with an intact Rb/E2F pathway to continuous exposure to CDK4/6 inhibitors for over a month, successfully inducing drug resistance.
The results were striking. Cells maintained on the inhibitors grew significantly slower than those taken off treatment, demonstrating that even resistant cells retain some sensitivity to the drugs. Further analysis revealed that resistant cells exposed to continued treatment remained longer in the G1 phase and divided at a slower rate. This was accompanied by reduced E2F activity and weaker Rb phosphorylation, effectively keeping the tumor suppressor active and halting cell cycle progression.
“Adding a CDK2 inhibitor reinforced this effect,” researchers noted, indicating a synergistic benefit to targeting both CDK4/6 and CDK2. Conversely, increasing the levels of a protein called Cyclin E, which collaborates with CDK2 to bypass the CDK4/6 blockade, diminished the effectiveness of the inhibitors.
A Shift in Treatment Paradigm?
The study fundamentally alters our understanding of drug resistance, suggesting that resistant tumors may still respond to treatment, albeit less robustly than non-resistant tumors. Rather than abandoning CDK4/6 inhibitors when resistance emerges, continuing—and potentially enhancing—treatment with the addition of a CDK2 inhibitor could slow down cell division and delay disease progression. This approach may explain positive outcomes observed in clinical trials where CDK4/6 inhibitors were continued despite resistance (Kim et al., 2023).
However, the researchers caution that this strategy may not be universally effective. Tumors with mutations in the Rb gene may not respond to this approach. Furthermore, the influence of endocrine therapy on the combined inhibition of CDK2 and CDK4/6 remains unclear. Identifying reliable biomarkers to predict treatment response is crucial (Zhang et al., 2023).
Ultimately, the findings underscore the importance of personalized medicine, tailoring treatment strategies to the unique biological characteristics of each tumor. While more research is needed to assess the safety and efficacy of this approach in patients, the study offers a compelling rationale for exploring combination therapies that target multiple points within the cell cycle. Even a modest slowdown in cell division, researchers emphasize, can have meaningful therapeutic effects, offering a valuable advantage in the fight against drug resistance.
